Original Article: PDF OnlyCombined Use of Thyroid Hormone and ECTStern, Robert A. Ph.D.; Steketee, Mareah C. Ph.D.*; Durr, Amy L. M.S., R.N.†; Prange, Arthur J. Jr M.D.†; Golden, Robert N. M.D.†,†Author Information Department of Psychiatry and Human Behavior, Brown University School of Medicine Providence, Rhode Island; *Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina; and the †Department of Psychiatry and the †General Clinical Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A. Convulsive Therapy: December 1993 - Volume 9 - Issue 4 - p 285-292 Buy Abstract Neurocognitive deficits, including acute confusion and memory impairment, remain important effects of electroconvulsive therapy (ECT). Laboratory and clinical research demonstrates interactions among neurocognitive functioning, the hypothalmic-pituitary-thyroid axis, depressive mood, and ECT. Preclinical studies have demonstrated that exogenous triiodothyronine (T3) administered to animals receiving electroconvulsive shock (ECS) protects against ECS-related amnesia and accelerates the “antidepressant effects” of ECS, possibly due to alterations in catecholamine and/or indoleamine neurotransmission. Clinical data suggest that combined treatment with T3 and ECT results in increased clinical efficacy of ECT and diminished neurocognitive side effects. © Lippincott-Raven Publishers.